Startseite

Regulatorische Updates

Regulatorische Entwicklungen von FDA, EMA, TGA und weltweit

UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
ANI PHARMS Diflorasone Diacetate Cream (ANDA076263) Discontinued
ANI PHARMS' diflorasone diacetate 0.05% topical cream (product 001) is listed as discontinued in FDA records. Multiple labeling submissions under ANDA076263 have been approved.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
FDA Approves Manufacturing and Labeling Submissions for Mellaril‑S Oral Suspension (NDA 017923)
The FDA has approved several manufacturing (CMC) and labeling submissions for the discontinued oral suspension Mellaril‑S, containing thioridazine, under NDA 017923.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
FDA Approves Supplemental Manufacturing Submissions for Discontinued Sodium Chloride 0.45% Irrigation Solution
The FDA has approved a series of supplemental manufacturing (CMC) and labeling submissions for the discontinued irrigation product SODIUM CHLORIDE 0.45% in plastic containers.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA078902 for Paroxetine Hydrochloride Tablets
The FDA has approved ANDA078902 for generic paroxetine hydrochloride tablets (10‑40 mg) manufactured by Mylan Pharmaceuticals.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
South Korea widens insurance coverage for rare disease, cancer drugs
South Korea’s Ministry of Health and Welfare announced faster reimbursement for Dravet syndrome treatment Fintepla‑Ac and broader coverage for blood‑cancer and pediatric‑leukemia drugs.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
KADA Marks 1-Year of Fair Play Ground Anti‑Doping Center
The Korea Anti-Doping Agency’s experiential anti‑doping education space, Fair Play Ground, celebrated its first year, having welcomed over 37,000 visitors since its August 26 opening.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
Health Insurance False Claims Detected at 839 Korean Clinics and Pharmacies Over Four Years
839 medical institutions in Korea were found to have submitted false health‑insurance claims totaling 34.79 billion won, with clinics accounting for 42.85% of the amount.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
South Korea's Health Ministry Reaffirms No Final Decision on Expanding Telemedicine Drug Delivery
The Ministry of Health and Welfare says expansion of medication delivery for telemedicine remains under discussion, with stakeholder input to be gathered via a public‑private council.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA077545 for Ondansetron Hydrochloride Tablets
FDA approved application ANDA077545 from Hikma International Pharmaceuticals for discontinued oral ondansetron tablets (4 mg, 8 mg, 24 mg) with multiple labeling supplements approved.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
FDA Approves Teva Generic Olanzapine (ANDA 077243)
The FDA has approved Teva Pharmaceuticals’ generic olanzapine oral tablets (5‑20 mg) under ANDA 077243, with several labeling supplements filed since 2014.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA 076942 for Ketoconazole 2% Topical Shampoo
The FDA has approved ANDA 076942 for a prescription 2% ketoconazole shampoo, marketed by Cosette Pharmaceuticals. Submission history includes labeling updates through 2020.
UPDATED
Regulatorische Updates
12. Sept. 2026•1 Min. Lesezeit
FDA Approves OSTEOSCAN (NDA 017454) as Radiopharmaceutical Injection
FDA granted priority approval to OSTEOSCAN, a technetium‑99m etidronate injectable, on Sep 28 1973; later supplemental filings updated labeling, manufacturing and efficacy. Product now discontinued.